Pleural Carcinomatosis Tissue Banking

Last updated: November 22, 2024
Sponsor: Hospices Civils de Lyon
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lung Disease

Carcinoma

Pleural Effusion

Treatment

Conserving routinely performed pleural biopsies in our biological resources center to realize multiomics and bioinformatics analyzes secondarily

Clinical Study ID

NCT04844827
69HCL21_0116
2021-A00761-40
  • Ages 18-110
  • All Genders

Study Summary

Malignant pleural effusion is a common evolution of various cancers and is associated with poor prognosis and quality of life. About 28% of patients with primary malignancy will develop pleural metastasis. Malignant pleural effusion mostly occurs in lung, breast, ovarian and gastric cancers. Median survival ranges from 3 to 13 months according to primary malignancy. Currently, the therapeutic approach is mainly palliative with videothoracoscopic talc pleurodesis or indwelling pleural catheters insertion eventually associated with systemic chemotherapy if patient's general condition allows.

In a early-disseminated tumor cells profile, metastatic cells can accumulate alterations at a distant site and have a different profil from the original tumor cells. Metastatic cells can also accumulate alterations in the course if systemic treatments. Consequently, they may respond differently to drugs.

Recently, EGFR mutations and ALK status discordance between primary tumors and pleural metastases have been demonstrated in a significant portion of lung adenocarcinomas. These studies, realized on malignant pleural effusion isolated cells, enabled us to hypothesize a possible intratumoral heterogeneity within pleural metastases, but no study has been carried out on pleural tissue.

Our aim is to create a biocollection with tissues from pleural carcinomatosis in order to subsequently allow multiomics and bioinformatics analyzes and to characterize a possible intratumoral heterogeneity in pleural metastasis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female over 18 years old

  • Malignant pleural effusion with or without prior histological or cytologicaldiagnosis

  • Patient eligible for a pleural biopsy for diagnostic purposes and validated in amultidisciplinary consultation meeting

  • Having given their free and informed writing consent

  • Affiliated to a social security system or assimilated

Exclusion

Exclusion Criteria:

  • Malignant pleural mesothelioma

  • Contraindication to general anesthesia

  • Pregnant or breastfeeding woman, or is of child bearing potential and who did notagree to use highly effective methods of birth control throughout the study.

  • Patient participating in a interventional study likely to interfere with this study

  • Patient benefiting from a legal protection measure (guardianship or curatorship)

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Conserving routinely performed pleural biopsies in our biological resources center to realize multiomics and bioinformatics analyzes secondarily
Phase:
Study Start date:
November 17, 2022
Estimated Completion Date:
November 17, 2025

Connect with a study center

  • Louis Pradel Hospital

    Bron, 69500
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.